The gamma-aminobutyric acid type A (GABA-A) receptor is the principal mediator of rapid inhibitory neurotransmission in the central nervous system. It is a ligand-gated ion channel of the Cys-loop superfamily, assembled as a pentameric complex most commonly comprising two α subunits, two β subunits, and one γ subunit arranged around a central chloride-permeable pore.³ When GABA binds to sites at the α-β subunit interfaces, the channel opens and allows chloride influx down its electrochemical gradient, hyperpolarizing the neuronal membrane and reducing the probability of action potential generation.

The benzodiazepine binding site is located at the interface between the α and γ2 subunits, a position distinct from the orthosteric GABA binding site. Benzodiazepines are positive allosteric modulators: they do not directly open the chloride channel but instead increase the frequency of channel opening in the presence of GABA.³ This allosteric mechanism is clinically important because it means benzodiazepine activity is intrinsically dependent on endogenous GABA tone — in the absence of GABA, benzodiazepines alone have minimal effect, which partially underlies their superior safety margin compared to barbiturates (which can directly activate the channel at high concentrations).⁴

The subunit composition of the GABA-A receptor confers pharmacological specificity. Receptors containing α1 subunits mediate sedation, anterograde amnesia, and anticonvulsant effects; those containing α2 and α3 subunits mediate anxiolytic and muscle relaxant effects; and α5-containing receptors, concentrated in hippocampal circuits, appear to contribute to learning and memory processes.⁵ Classic benzodiazepines bind non-selectively to all α subunit isoforms that contain a histidine residue at a conserved position (α1, α2, α3, α5), which is why a single benzodiazepine produces the full spectrum of sedation, anxiolysis, amnesia, anticonvulsant activity, and muscle relaxation simultaneously. This non-selectivity is in contrast to the Z-drugs discussed in Part 2, which have relative α1 selectivity.

Functionally, the net effect of benzodiazepine-enhanced GABA-A activity is widespread CNS depression that is regionally modulated by the distribution of GABA-A receptor subtypes. Limbic areas rich in α2/α3 receptors are primarily responsible for anxiolytic effects, the reticular activating system for sedation, the cerebellum for ataxia, and spinal interneurons for muscle relaxation.

ANXIETY DISORDERS: Benzodiazepines are effective anxiolytics across virtually all anxiety disorder categories — generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and situational anxiety — due to their rapid onset of anxiolytic action.⁹ However, first-line pharmacotherapy for chronic anxiety disorders is now established as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), with benzodiazepines reserved for adjunctive use during the latency period before antidepressant effect is established (typically 2–4 weeks), or for acute situational anxiety (e.g., flight phobia, medical procedures).⁹ Chronic benzodiazepine use for anxiety is associated with tolerance to anxiolytic effects, escalating dosing, and a withdrawal syndrome that can mimic the original anxiety disorder — complicating both assessment and tapering.

For panic disorder, alprazolam and clonazepam have established efficacy and are FDA-approved for this indication. Clonazepam's longer half-life confers an advantage in minimizing inter-dose anxiety and rebound panic that can occur with shorter-acting agents.

INSOMNIA: As hypnotics, benzodiazepines reduce sleep-onset latency and increase total sleep time, primarily by reducing stage N1 and N2 sleep time while suppressing slow-wave sleep (N3) and rapid eye movement (REM) sleep.¹⁰ The clinical consequence is that although benzodiazepines may help patients fall asleep and stay asleep, the resulting sleep architecture is less restorative. Chronic use is further complicated by rebound insomnia upon discontinuation — often worse than the original complaint — which reinforces continued use. Current clinical practice guidelines endorse cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacological agents reserved for short-term use (typically ≤4 weeks) in patients who fail or cannot access behavioral therapy.¹⁰ Among benzodiazepines, temazepam remains one of the more commonly used agents for sleep, given its intermediate half-life and lack of active metabolites.

ACUTE SEIZURE MANAGEMENT: Benzodiazepines are first-line agents for termination of acute seizures, status epilepticus, and seizure clusters. IV lorazepam and IM midazolam have the strongest evidence base for acute seizure management in both pediatric and adult populations.¹¹ The landmark RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial) demonstrated that intramuscular midazolam was non-inferior to intravenous lorazepam for termination of status epilepticus in the prehospital setting, and was actually more effective due to the delays inherent in establishing IV access.¹¹ Diazepam rectal gel and midazolam intranasal/buccal formulations are established options for out-of-hospital rescue therapy for patients with epilepsy and known seizure clusters.

For status epilepticus management in the hospital, IV lorazepam 0.1 mg/kg (maximum 4 mg per dose, may repeat once) or IV diazepam 0.15–0.2 mg/kg are standard initial treatments, followed by a longer-acting antiseizure agent (fosphenytoin, valproate, levetiracetam, or lacosamide) to prevent recurrence.

ALCOHOL WITHDRAWAL: Benzodiazepines are the agents of choice for management of alcohol withdrawal syndrome (AWS), including prevention and treatment of withdrawal seizures and delirium tremens (DT).¹² The mechanism is direct: alcohol potentiates GABA-A receptor (GABA-A) activity, and chronic alcohol use leads to compensatory downregulation of GABA-A receptors and upregulation of excitatory NMDA glutamate receptors. Upon alcohol cessation, the resulting imbalance — reduced GABAergic inhibition and enhanced glutamatergic excitation — produces the hyperadrenergic state of AWS. Benzodiazepines correct this imbalance by restoring GABAergic tone.

Long-acting agents (diazepam, chlordiazepoxide) are preferred in medically stable patients because their extended half-lives produce a self-tapering effect that reduces both the severity and the clinical management burden of withdrawal. The Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) scale is used for symptom-triggered dosing, which has been shown to reduce total benzodiazepine consumption and length of treatment compared to fixed-schedule protocols.¹² In patients with hepatic impairment or elderly patients where long-acting agent accumulation is a concern, the LOT agents — particularly lorazepam or oxazepam — are preferred despite their shorter half-lives requiring more frequent dosing. Fixed-dose phenobarbital loading is an increasingly used alternative protocol, particularly in ICU settings, and is discussed further in CNS-03.

PROCEDURAL SEDATION AND ANXIOLYSIS: Midazolam is the most widely used benzodiazepine for procedural sedation and preoperative anxiolysis due to its rapid onset (1–2 minutes IV), short duration (20–30 minutes), and reliable amnestic properties. It is water-soluble at pharmaceutical pH (unlike diazepam, which requires propylene glycol as a solvent and causes venous irritation), making it the preferred parenteral benzodiazepine in most clinical settings. Midazolam undergoes rapid hepatic metabolism to 1-hydroxymidazolam, which is then glucuronidated; the 1-hydroxymidazolam glucuronide is pharmacologically active and can accumulate in renal failure, contributing to prolonged sedation in ICU patients receiving continuous midazolam infusions.

MUSCLE RELAXATION: The centrally mediated muscle relaxant effects of benzodiazepines are utilized in conditions such as spastic cerebral palsy, tetanus, and stiff-person syndrome. Diazepam is the most commonly used agent for this purpose. Benzodiazepines act on spinal cord interneurons and supraspinal circuits rather than directly at the neuromuscular junction, distinguishing them from peripherally acting agents such as dantrolene.

ELDERLY PATIENTS: Benzodiazepines are consistently listed on the American Geriatrics Society Beers Criteria as medications to avoid in older adults.¹⁴ The basis for this recommendation is multifactorial. Age-related pharmacokinetic changes — reduced hepatic oxidative metabolism, decreased albumin, increased body fat — lead to higher free drug levels and prolonged elimination of long-acting agents. Age-related pharmacodynamic changes — increased CNS sensitivity to GABAergic agents due to neuronal loss and altered receptor expression — compound this effect. The clinical consequence is a disproportionate risk of sedation, cognitive impairment, psychomotor slowing, falls, and fractures. Benzodiazepine use in older adults is independently associated with an increased risk of hip fracture, motor vehicle accidents, and dementia (though the causal versus confounded nature of the dementia association remains debated).¹⁴ When benzodiazepines are unavoidable in elderly patients, short-acting agents without active metabolites (lorazepam, oxazepam) at the lowest effective dose are preferred.

HEPATIC IMPAIRMENT: As noted, agents dependent on hepatic oxidative metabolism (CYP3A4 (cytochrome P450 3A4), CYP2C19 (cytochrome P450 2C19)) — diazepam, chlordiazepoxide, alprazolam, triazolam — are subject to substantially impaired clearance in liver disease, with risk of accumulation and prolonged sedation. The LOT agents (lorazepam, oxazepam, temazepam), which are glucuronidated, are preferred. However, even glucuronidation may be impaired in severe hepatic failure (Child-Pugh C), and all benzodiazepines should be used with caution in advanced cirrhosis given the risk of precipitating or worsening hepatic encephalopathy.

PREGNANCY: All benzodiazepines cross the placenta and are detectable in fetal circulation. Chronic use during the third trimester can produce neonatal withdrawal syndrome (hypotonia, feeding difficulties, respiratory depression, jitteriness) and neonatal abstinence syndrome. The teratogenic risk of benzodiazepines in the first trimester, while historically debated in relation to oral cleft defects, has not been definitively established in well-controlled studies.⁷ For acute seizure management in pregnancy (including eclampsia-associated seizures), the benefits of treatment clearly outweigh risks. For non-urgent indications, the goal should be avoidance or minimization of benzodiazepine exposure. Benzodiazepines are present in breast milk and can cause neonatal sedation; use during lactation warrants careful risk-benefit assessment.

While the pharmacokinetic principles covered in Section 3 provide the conceptual framework for benzodiazepine selection, clinicians require familiarity with the specific dosing parameters, formulations, and clinical characteristics of the most widely used individual agents. The profiles below cover the benzodiazepines most frequently encountered in primary care, emergency, and inpatient settings.

Diazepam is the prototypical long-acting benzodiazepine and remains among the most versatile agents in the class. Its high lipophilicity produces rapid CNS penetration after IV administration, with onset within 1–3 minutes. The parent compound has a half-life of 20–100 hours, and its primary active metabolite desmethyldiazepam has a half-life of 36–200 hours, meaning effective drug activity persists for days to weeks after the last dose in patients on chronic therapy.⁸ This prolonged coverage is advantageous in alcohol withdrawal management due to the self-tapering effect, but creates substantial accumulation risk in elderly patients and those with hepatic disease. Oral bioavailability is approximately 100%; IM absorption is erratic and not recommended for acute dosing. IV diazepam requires propylene glycol as a solvent, causing venous irritation and potential cumulative toxicity at high doses. Rectal gel (Diastat) and nasal spray (Valtoco) are approved for rescue therapy of acute repetitive seizures. Standard oral anxiolytic dosing is 2–10 mg two to four times daily; IV dosing for status epilepticus is 0.15–0.2 mg/kg.

Lorazepam is intermediate in lipophilicity and half-life (10–20 hours), undergoes direct glucuronidation without active metabolites, and is available in oral, IV, and IM formulations. IV lorazepam is the preferred agent for hospital management of status epilepticus (0.1 mg/kg IV, maximum 4 mg per dose, may repeat once), offering reliable efficacy with more predictable pharmacokinetics than diazepam in this acute setting.¹¹ IM lorazepam has good bioavailability unlike IM diazepam, making it useful when IV access is unavailable. As a LOT agent, lorazepam is preferred in patients with hepatic disease, elderly patients, and those with significant medical comorbidities. For procedural anxiety, 0.5–2 mg IV or IM is typical. For alcohol withdrawal in patients where long-acting agents carry accumulation risk, 1–4 mg IV or IM every 4–8 hours titrated by CIWA-Ar score is standard. Sublingual lorazepam (0.5–1 mg) provides rapid anxiolysis for acute situational anxiety in outpatient settings.

Midazolam is the shortest-acting parenteral benzodiazepine in routine clinical use (half-life 1.5–2.5 hours) and the agent of choice for procedural sedation and preoperative anxiolysis. Unlike diazepam, midazolam is water-soluble at pharmaceutical pH, eliminating the venous irritation associated with propylene glycol-based formulations. IV onset is within 1–2 minutes; IM onset is 5–15 minutes. Standard IV procedural sedation dosing is 0.5–2 mg titrated to effect, with additional 0.5–1 mg increments as needed. Intranasal midazolam (0.2 mg/kg, maximum 10 mg) is used for pediatric procedural sedation and acute seizure management, with bioavailability of approximately 50–60% via this route. Midazolam undergoes CYP3A4 (cytochrome P450 3A4) hepatic metabolism to 1-hydroxymidazolam, which is glucuronidated to an active glucuronide that accumulates in renal failure — a clinically important consideration in ICU patients receiving continuous midazolam infusions, where this accumulation produces prolonged sedation well beyond what the plasma half-life alone would predict.⁶

Alprazolam is a high-potency, intermediate-acting benzodiazepine (half-life 6–27 hours) FDA-approved for generalized anxiety disorder and panic disorder. Its high potency relative to diazepam (alprazolam 0.5 mg is approximately equivalent to diazepam 10 mg) combined with its relatively short half-life and rapid CNS penetration makes it among the highest-risk benzodiazepines for dependence development, inter-dose withdrawal, and difficulty with discontinuation. The extended-release formulation (Xanax XR, 0.5–3 mg once daily) was developed to reduce inter-dose anxiety and improve tolerability during tapering. Strong CYP3A4 inhibitors (azole antifungals, certain macrolides) can substantially increase alprazolam plasma levels and duration of effect, and this interaction has been implicated in overdose fatalities. The maximum recommended dose is 4 mg/day for anxiety disorders and 10 mg/day for panic disorder, though doses above 4 mg/day are associated with substantially higher dependence risk and are rarely justified in primary care settings.

Clonazepam is a high-potency benzodiazepine with a relatively long half-life (20–60 hours) that is FDA-approved for panic disorder and several seizure types including Lennox-Gastaut syndrome and akinetic and myoclonic seizures. Its extended half-life reduces the inter-dose anxiety that complicates alprazolam therapy in panic disorder, making once or twice daily dosing feasible. For panic disorder, starting doses of 0.25 mg twice daily with titration to 1–4 mg/day are typical. Clonazepam is also widely used off-label for restless legs syndrome and rapid eye movement (REM) sleep behavior disorder. Despite its longer half-life, physical dependence and a challenging discontinuation syndrome are significant concerns with chronic use — the extended half-life does not eliminate dependence risk, it merely modulates the time course of withdrawal symptoms. Clonazepam is metabolized by CYP3A4 and nitroreduction; it has no clinically active metabolites.

Oxazepam (Serax, half-life 5–15 hours) undergoes direct glucuronidation without CYP-mediated oxidative metabolism and has relatively slow oral absorption (Tmax 1–4 hours), making it suboptimal for situations requiring rapid onset. Standard anxiolytic dosing is 10–30 mg three to four times daily. Its primary clinical role is as the preferred benzodiazepine in patients with significant hepatic impairment or in elderly patients where accumulation of CYP-dependent metabolites poses unacceptable risk. Temazepam (Restoril, half-life 8–22 hours) is used primarily as a hypnotic for sleep-onset and sleep-maintenance insomnia. Standard hypnotic dosing is 7.5–30 mg at bedtime; the 7.5 mg dose is recommended for elderly patients. Its intermediate half-life provides overnight sleep coverage without the excessive next-day residual sedation of longer-acting agents, while avoiding the rebound insomnia seen with ultra-short-acting triazolam. Both agents, as LOT members, are preferred when hepatic metabolism is compromised and in elderly patients where glucuronidation is relatively preserved compared to CYP-dependent oxidative pathways.